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Dr R. Duane Davis (Durham, NC). First, I congratulate you on
an excellent presentation. This is not a shocking finding, in a team
sport like heart transplant, that better outcomes are associated with
higher volumes. I want to focus a little bit more on how you de-
fined what was a large-volume versus a small-volume center.
There was a recent report in the Journal that used essentially the
same UNOS data set that you did. They divided it into quartiles;
in fact, the low volume was approximately 15 and less, and then
marched it up, with the high-volume centers approximately 34
and over. For each of the groups, there was a reduction in the actual
mortality risk. You have added recipient risk, as quantified by your
IMPACT score, to the analysis. High-risk recipients would seem to
do better in centers that are doing higher volumes of procedures.
Did your analysis actually look at where the volume threshold ef-
fect was? Did it continue to decline as the volumes increased? If
you look at the International Society for Heart and Lung Trans-
plantation registry, which puts out the slide every year associating
recipient mortality with center volume, the place where it plateaus
is approximately 35 to 40. I would assume that that would be sim-
ilar in this analysis, but you have tended to focus more on just the
very small versus moderate sized transplant programs.166 The Journal of Thoracic and Cardiovascular SurgDrArnaoutakis. Thank you, Dr Davis, for your kind comments
and important points and questions. With respect to our stratifica-
tion methods, we counted each center as a single observation when
we made our stratifications. We have done our center volume anal-
yses in this fashion in the past, and we believe that it is actually
very important to do it in this fashion. When we divide into tertiles
according to defining average volume in this fashion, there is
roughly a third, or approximately 47 centers, that are above 15
heart transplants per year. When each individual patient is counted
as a single observation, that significantly skews the cut points in
the upward direction. If we were then to define centers according
to those cut points, we would actually limit significantly the num-
ber of centers defined as high volume for the purposes of this study.
So that was why we defined them as such.
In our analysis, we did perform both continuous and categoric,
or dichotomous, cut points for center volume. Because we incor-
porated interaction terms, it becomes increasingly complicated
and difficult to explain simply the effect modification when ex-
amining the interaction among multiple continuous variables.
With regard to your point about the International Society for
Heart and Lung Transplantation registry, however, we did exam-
ine that in a continuous fashion, with spline terms as well as
graphically inspecting Lowes S curves, and it looks to us, espe-
cially for the high-risk recipients derived from UNOS data, which
obviously varies somewhat from the international registry, that
there does seem to be a plateau that occurs between 20 to 30 pro-
cedures per year, which still limits the number of centers al-
though not as much so as when we make cut points above 45,
where then we are only talking about a handful of centers, which
may limit access to care for some patients who are not near these
centers.
DrDavis.The next component of this is that we shouldn’t really
be in the business of trying to shut down programs. It should be in
the idea of how do we improve the quality of all the programs. So
how can we essentially raise the boat? And are there things, and
this is something that you are not going to get out of the UNOS
data set but you can make some assumptions, that are necessary
to be able to do this well? And what can we learn from this type
of data set analysis to say, okay, if you are going to be in the busi-
ness of heart transplant, these are the critical items that you need to
be doing if you are going to be really successful? Again, my con-
gratulations on an excellent presentation.
Dr Arnaoutakis. Thank you again. Your point is absolutely
right and well taken. The study intention and these findings are
not meant to impugn centers of any volume whatsoever. If you
look closely, there are several centers in the low-volume category
that achieve excellent outcomes. And so you are getting at a very
important point, that these findings don’t prove any causation but
show associations. What we need to pursue from here on is to iden-
tify the processes of care that we believe are intimately involved
with these findings. Oneway to do this is to go back to institutional
series, where we have access to variables that are not included in
the UNOS database, which although it has many variables does
not encompass all variables. For example, we have looked in our
institutional series at the distance that patients live from the trans-
plant center and have found an association with greater rates of re-
jection. So there may be some follow-up study that can be
performed at individual centers both in the high-volume end ofery c January 2012
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these processes of care.
It is difficult with the UNOS database to glean any information
regarding independent surgeon experience and surgeon volume,
which may play some role. As well, perioperative care may vary
across the spectrum of different centers with different volumes,
and we believe that this is also intimately involved with these find-
ings. And so some of the pathways and structures that are set up at
various intensive care units may shed more light on these
differences.
We do believe that these findings begin to shed light on the out-
come differences that we have observed, in that the differences
seem to be dictated in large part by outcomes of recipients who
are at the highest end of the risk spectrum.
Dr Craig R. Smith (New York, NY). Very briefly, did you con-
sider the possibility that a low-volume center that had been in busi-
ness for a long timemight be okay, which youmight see by looking
at total historical transplant volume or total number of survivors?
Dr Arnaoutakis. We didn’t specifically look at that. We did
look over time, and it is difficult to tell whether a center has
gone from 1 to 0 transplants per year if that center remainsThe Journal of Thoracic and Caopen.We looked at the patterns, and wemade assumptions accord-
ing to whether they had closed temporarily and then reopened. We
did incorporate time into our models, but not with the specific
question that you asked. That is an important point, however, for
understanding factors that may play into low-volume centers
that achieve excellent outcomes. That is something that we are go-
ing to look into further.
Dr Giovanni Battista Luciani (Verona, Italy). I enjoyed your
presentation. On one of the first slides, in the lower center volumes
there was a higher prevalence of congenital heart disease as an in-
dication for surgery. I was intrigued by that, because it has been
recognized that this is an increased risk factor for mortality early
and late after transplant. Did you try running your analysis exclud-
ing that diagnosis, and would it come out the same? Thank you.
Dr Arnaoutakis. Thank you for pointing that out. We were in-
trigued by that as well. We didn’t expect to see such a magnitude of
difference. Congenital heart disease is accounted for in our risk
score, and so we actually did not perform the analysis excluding
those patients, because we considered that it was already adjusted
for. So I don’t believe that that would be driving any of these find-
ings, but it is an important thing that we could examine.rdiovascular Surgery c Volume 143, Number 1 167
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